- Home
- CHI vs DSGN Comparison
CHI vs DSGN Comparison
Compare CHI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | DSGN |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 819.6M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHI | DSGN |
|---|---|---|
| Price | $12.81 | $10.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 165.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $3.33 |
| 52 Week High | $12.75 | $17.25 |
Technical Indicators
Market Signals| Indicator | CHI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.21 | 37.06 |
| Support Level | $10.84 | $9.36 |
| Resistance Level | N/A | $10.59 |
| Average True Range (ATR) | 0.25 | 1.29 |
| MACD | 0.03 | -0.38 |
| Stochastic Oscillator | 96.56 | 6.83 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.